Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics, Inc. President, R&D Crystal Adam reported an exercise-and-sell transaction in company common stock. She exercised stock options for 27,000 shares at $5.20 per share, then sold a total of 27,000 shares in open-market trades at weighted-average prices around $29–$30.
The filing shows two sale blocks: 7,371 shares at a weighted-average price of $30.2464 and 19,629 shares at $29.3424. After these transactions, Adam directly holds 115,743 shares of common stock. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they were scheduled in advance.
Tango Therapeutics director Robert Azelby reported equity awards from the company. He received 5,740 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share.
The RSUs will vest in three substantially equal annual installments following the grant date, as long as he remains in continuous service. He was also granted a stock option covering 35,910 shares of Common Stock at an exercise price of $27.97 per share. This option vests in 36 substantially equal monthly installments over three years, subject to continued service, and expires on June 19, 2036. These are compensation-related grants, not open‑market purchases.
Tango Therapeutics, Inc. director Robert Azelby has filed a Form 3, which is an initial statement of beneficial ownership as a company insider. The filing lists him as a director but does not report any stock transactions or current holdings in this excerpt.
Tango Therapeutics, Inc. expanded its Board of Directors to seven members and appointed biopharmaceutical executive Robert Azelby as a Class II director, with a term running until the 2029 annual meeting of stockholders. The Board determined he is independent under Nasdaq listing standards and named him to the Compensation Committee and the Nominating and Corporate Governance Committee, effective June 23, 2026.
Under the non-employee director compensation program, he will receive a stock option for 35,910 shares at an exercise price of $27.97 per share, vesting monthly over three years, and an RSU award for 5,740 shares vesting annually over three years, along with cash retainers for Board and committee service. The accompanying press release highlights his three decades of oncology and commercial leadership and notes his appointment comes as Tango advances its investigational PRMT5 inhibitor vopimetostat toward potential late-stage development for MTAP-deleted cancers, including pancreatic cancer.
TNGX affiliate filed a Form 144 reporting proposed sales of Common Stock. The notice lists three transactions by NEXTECH CROSSOVER I SCSP: 06/11/2026 500,000 shares for $15,018,000; 06/12/2026 500,000 shares for $14,870,050; and 06/15/2026 2,500,000 shares for $75,164,250.
The filing identifies these as Common Stock sales tied to prior private placements and lists broker-dealer information. The notice is procedural under Form 144 and reports the affiliate's intended dispositions on the stated dates.
TNGX submitted a Form 144 notice for proposed sales of Common Stock effective 06/11/2026. The filing lists a $51,523,582.08 figure and multiple lots: 1,791,726 shares (entry), 1,625,739 shares tied to a stock option exercise with a 06/11/2026 date, and 165,987 shares described as restricted stock from 04/01/2017. The excerpt also discloses a reported sale by Daniella Beckman of 4,446 shares on 06/10/2026 for $133,380.00.
The filing names Morgan Stanley Smith Barney LLC as broker and indicates NASDAQ as the market. This Form 144 notifies the SEC and provides holder/sale details; it does not itself execute transfers.
Tango Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 additional shares. The shares are priced at $30.00 each and the pre-funded warrants at $29.999 each, reflecting a $0.001 exercise price.
The company also granted underwriters a 30-day option to buy up to 3,000,009 additional shares. Tango estimates net proceeds of approximately $566.5 million, to be used for general corporate purposes, including research and development, pivotal trial expenses, commercialization preparation, and capital expenditures. Based on its current plan, it believes existing funds plus this offering will support operations into 2030.
Tango Therapeutics is offering 18,166,667 shares of common stock and pre-funded warrants to purchase 1,833,395 shares. The public offering price is $30.00 per share (pre-funded warrant price $29.999) and the offering is being made pursuant to a shelf registration statement. The underwriters may purchase up to an additional 3,000,009 shares. Net proceeds to the company are estimated at approximately $566.5 million, which the company intends to use for general corporate purposes, R&D, pivotal trial expenses and potential commercialization preparation.
Issuer submitted a Form 144 notice reporting proposed sales of common stock. The filing lists a stock option exercise tied to 914 shares dated 06/10/2026 and restricted stock of 3,532 shares dated 03/16/2017. The broker listed is Morgan Stanley Smith Barney LLC and an amount of $133,380.00 appears in the record.
Tango Therapeutics director John B. Ketchum received an equity grant consisting of 4,000 restricted stock units and an option for 25,000 shares of Common Stock. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, subject to continued service. The stock option, with a $20.22 exercise price, vests in 12 equal monthly installments beginning July 5, 2026 and expires on June 5, 2036. Following these grants, Ketchum directly holds 24,937 shares of Common Stock.